Kindred Biosciences, Inc. (NASDAQ: KIN) and Astaria Global, LLC, announce an affiliate relationship to market and sell Alpha2EQ Therapy Products. Under the agreement, veterinarians will be able to purchase Alpha2EQ through collaboration with their KindredBio representative.
“We are delighted to partner with Astaria Global in bringing their innovative regenerative therapy to equine veterinarians,” said Jenna Mutch, KindredBio’s Vice President of Commercial. “Together, we are committed to supporting the health of horses and broadening access to medical care for the equine community.”
Alpha2EQ Therapy was launched in 2019. In this innovative new process, the body’s naturally occurring molecule, Alpha-2 Macroglobulin (α2M), is isolated and concentrated from the equine patient’s own blood. The concentrated Alpha2EQ serum is administered by a veterinarian at the injury site by injection to manage articular and soft tissue injuries in the horse.
“Our patented and advanced plasma technology is going to be instrumental in treating lameness, osteoarthritis, joint pain, and other issues that many animals face, especially in competition horses,” stated Bill Cramer, CEO of Astaria Global. “We are excited to join forces with KindredBio and make Alpha2EQ more widely available to equine veterinarians.”
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com.
About Astaria Global
At Astaria Global, we apply science and diverse experience to bring therapies to animals that extend and significantly improve their lives. Working with owners, researchers and animal care professionals, our mission is to advance world class regenerative therapies, biologics, and innovative animal care products through clinical discovery, product development and global distribution. Our commitment to animal science is second only to our passion for wellness and well-being of these beloved animals. In addition to Astaria’s core capabilities, the Company is actively pursuing pioneering partnerships and investments that accelerate the delivery of our strategy, as illustrated by the introduction of the Alpha2EQ and Alpha2CP.
We routinely post information that might be important to animal care providers, the research community and investors on our website at www.astariaglobal.com.
